|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
PM00104
|
MedKoo Code#: 202290
|
|
Name: PM00104
|
|
CAS#:
Synonym:
Brand name: Zalypsis
IUPAC/Chemical name:
(6aS,7R,13S,14S,16R)-8,14-dihydroxy-9-methoxy-4,10,17-trimethyl-16-(((E)-3-(3-(trifluoromethyl)phenyl)acrylamido)methyl)-6a,7,12,13,14,16-hexahydro-6H-7,13-epiminobenzo[4,5]azocino[1,2-b][1,3]dioxolo[4,5-h]isoquinolin-5-yl
acetate
|
|
Chemical structure |
Theoretical analysis
|
|
|
Chemical Formula: C37H38F3N3O8
Exact Mass: 709.26110
Molecular Weight: 709.71
m/z: 709.26110 (100.0%), 710.26445 (40.0%),
711.26781 (7.8%), 711.26535 (1.6%), 710.25813 (1.1%)
Elemental Analysis: C, 62.62; H, 5.40; F,
8.03; N, 5.92; O, 18.03
|
|
Availability and price:
This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
PM00104 is a
synthetic tetrahydroisoquinoline alkaloid related to the marine natural
compounds Jorumycin and the family of Renieramycins, obtained from
molluscs and sponges, respectively, with potential antineoplastic
activity. PM00104 reversibly binds to DNA and interferes with DNA
replication, transcription, and translation. DNA binding by this agent
does not trigger DNA damage checkpoint responses, hence PM00104 exhibits
a reversible cytotoxicity. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus) .
Current developer:
PharmaMar Inc
1: Yang C, Hornicek FJ, Wood KB, Schwab JH, Choy E,
Iafrate J, Rosenberg A, Nielsen GP, Xavier RJ, Mankin H, Duan Z.
Characterization and analysis of human chordoma cell lines. Spine (Phila
Pa 1976). 2010 Jun 1;35(13):1257-64. PubMed PMID: 20461036.
2: Duan Z, Choy E, Harmon D, Yang C, Ryu K, Schwab J, Mankin H, Hornicek
FJ. ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and
PM00104 (Zalypsis) in human cancer cell lines. PLoS One. 2009 Sep
9;4(9):e6967. PubMed PMID: 19742314; PubMed Central PMCID: PMC2734182.
3: Guirouilh-Barbat J, Antony S, Pommier Y. Zalypsis (PM00104) is a
potent inducer of gamma-H2AX foci and reveals the importance of the C
ring of trabectedin for transcription-coupled repair inhibition. Mol
Cancer Ther. 2009 Jul;8(7):2007-14. Epub 2009 Jul 7. PubMed PMID:
19584237.
4: Leal JF, García-Hernández V, Moneo V, Domingo A, Bueren-Calabuig JA,
Negri A, Gago F, Guillén-Navarro MJ, Avilés P, Cuevas C,
García-Fernández LF, Galmarini CM. Molecular pharmacology and antitumor
activity of Zalypsis in several human cancer cell lines. Biochem
Pharmacol. 2009 Jul 15;78(2):162-70. Epub 2009 Apr 11. PubMed PMID:
19427997.
5: Ocio EM, Maiso P, Chen X, Garayoa M, Alvarez-Fernández S, San-Segundo
L, Vilanova D, López-Corral L, Montero JC, Hernández-Iglesias T, de
Alava E, Galmarini C, Avilés P, Cuevas C, San-Miguel JF, Pandiella A.
Zalypsis: a novel marine-derived compound with potent antimyeloma
activity that reveals high sensitivity of malignant plasma cells to DNA
double-strand breaks. Blood. 2009 Apr 16;113(16):3781-91. Epub 2008 Nov
19. Erratum in: Blood. 2010 Jul 8;116(1):151. PubMed PMID: 19020308.
6: Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, Hornicek FJ.
Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug
resistant cell lines. Cancer Chemother Pharmacol. 2009 May;63(6):1121-9.
Epub 2008 Oct 1. PubMed PMID: 18828019.
7: Faircloth G, Cuevas C. Kahalalide F and ES285: potent anticancer
agents from marine molluscs. Prog Mol Subcell Biol. 2006;43:363-79.
Review. PubMed PMID: 17153351.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
